Spots Global Cancer Trial Database for Sitravatinib in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sitravatinib in Metastatic Breast Cancer
Official Title: A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer
Study ID: NCT04123704
Interventions
Study Description
Brief Summary: This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer. All study participants will receive sitravatinib, 100 mg daily, until their cancer worsens, or until they develop intolerable side effects.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Baylor College of Medicine, Houston, Texas, United States
Contact Details
Name: C. Kent Osborne, MD
Affiliation: Baylor College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
